key: cord-0300063-7uodek49
authors: Gelanew, T.; Seyoum, B.; Mulu, A.; Mihret, A.; Abebe, M.; Wassie, L.; Gelaw, B.; Sorsa, A.; Merid, Y.; Muchie, Y.; Teklemariam, Z.; Tesfaye, B.; Osman, M.; Jebessa, G.; Atinafu, A.; Hailu, T.; Habte, A.; Kenea, D.; Gadissa, A.; Admasu, D.; Tesfaye, E.; Bates, T. A.; Bulcha, J.; Tschopp, R.; Tsehay, D.; Mullholand, k.; Howe, R.; Gentu, A.; Tafesse, F. G.; Abdissa, A.
title: High Seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
date: 2021-07-06
journal: nan
DOI: 10.1101/2021.07.01.21259687
sha: f6385220c8cacc4df58e0c0eee499558aaba814b
doc_id: 300063
cord_uid: 7uodek49

COVID-19 pandemic has a devastating impact on the economies and health care system of sub-Saharan Africa. Healthcare workers (HWs), the main actors of the health system, are at higher-risk because of their occupation. Serology-based estaimates of SARS-CoV-2 infection among HWs represent a measure of HWs level of exposure to the virus and a guide to the prevalence of SARS-CoV-2 in the community. This information is currently lacking in Ethiopia. This study aims to develop an in-house antibody testing assay and assess the prevalence of SARS-CoV-2 antibodies among Ethiopian high-risk front-line HWs. A cross-sectional seroprevalence study was conducted among HWs in five public hospitals located in different geographic regions of Ethiopia. Socio-demographic and clinical data were collected using questionnaire-based interviews. From consenting HWs, blood samples were collected between December 2020 and February 2021, the period between the two peaks of COVID-19 in Ethiopia. The collected sera were tested using an in-house immunoglobin G (IgG) enzyme-linked immunosorbent assay (ELISA) for SARS-CoV-2 specific antibodies on sera collected from HWs. Of 1,997 HWs who provided a blood sample, demographic and clinical data, 50.5% were female, 74.0% had no symptoms compatible with COVID-19, and 29.0% had history of contact with suspected or confirmed patient with SARS-CoV-2 infection. The overall seroprevalence was 39.6%. The lowest (24.5%) and the highest (48.0%) seroprevalence rates were found in Hiwot Fana Specialized Hospital in Harar and ALERT Hospital in Addis Ababa, respectively. Of the 821 seropositive HWs, 224(27.3%) had history of symptoms consistent with COVID-19. A history of close contact with suspected/confirmed COVID-19 cases was strongly associated with seropositivity (Adjusted odds Ratio (AOR) =1.4, 95% CI 1.1-1.8; p=0.015). High SARS-CoV-2 seroprevalence levels were observed in the five Ethiopian hospitals. These findings highlight the significant burden of asymptomatic infection in Ethiopia, and may reflect the scale of transmission in the general population.

CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. CoV-2 infection in suspected cases and contacts, as well as both outbound and inbound travelers. Given 153 the difficulty and cost of RT-PCR-based testing in resource-limited countries like Ethiopia, mildly 154 affected or asymptomatic individuals are not usually screened, and so the number of confirmed SARS-155

CoV-2 infections is likely vastly underestimated 6 . In this context, seroprevalence surveys are of the 156 utmost importance to assess the proportion of the population that have already developed antibodies 157 against the virus. 158

Evidence has shown that healthcare workers (HWs) are at higher risk of acquiring the infection than the 159 general population. This is because their work is likely to require close contact with SARS-CoV-2 160

infected patients at COVID-19 treatment centers, in emergency rooms and wards, and via virus-161 contaminated surfaces. If infected, they can pose a significant risk to vulnerable patients and co-workers 8 . 162

Thus, assessing the seroprevalence of SARS-CoV-2 antibodies among HWs in Ethiopia will help us 163

understand COVID-19 spread among health care facilities and to measure the success of public health 164

interventions. It will also provide an opportunity to compare the disease trajectory in a low-income 165 setting. A report from London, UK suggested that the rate of asymptomatic SARS-CoV-2 infection 166 among HWs reflects general community transmission rather than in-hospital exposure 9 . Therefore, a 167 serosurvey of SARS-CoV-2 was conducted amongst HWs in five public hospitals to estimate the 168

Seroprevalence of SARS-CoV-2 in urban Ethiopia. We then discuss the implications of our SARS-CoV-2 169 serosurveillance for frontline healthcare workers and the Ethiopian population at large. This cross-sectional study represents a joint effort between the Armauer Hansen Research Institute 173

(AHRI) and five public hospitals in Ethiopia, namely Gondar, Asella, Hawassa, Hiwot Fana (located in 174

Harar), and All Africa Leprosy and Tuberculosis Rehabilitation and Training Center (ALERT Center) 175

hospitals. These participating hospitals were selected because they are among the 11 hospitals located in 176 different regional states of the country, and are linked to the AHRI"s Clinical Research Network. Similar 177 seerosurvey studies for the remaining hospitals liked to the AHRI"s CRN are ongoing. Ethical approvals 178

were obtained from all institutions and written informed consent was obtained from each participant. All 179 hospital staff (n=7,898) from all five public hospitals were invited to take part in the study through office 180 memos and notice board announcements. However, only 24.4% of them were volunteered to provide 5 181 milliliter blood and demographic and clinical data. Demographic and clinical data were obtained using a 182 structured questionnaire based on WHO SARS-CoV-2 seroprevalence studies (World Health 183

Organization (WHO, the "Solidarity II" global serologic study for COVID-19) 10 . 184

Sample collection, storage, transportation, and inactivation 185 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.01.21259687 doi: medRxiv preprint Five milliliters of blood were collected in a serum collection tube from each participant using standard 186

procedures. Sera were separated by centrifugation and stored at -20 0 C until transferred to AHRI 187 laboratory in Addis Ababa, Ethiopia, in a cold box. Inactivation of infectious viruses in serum was 188 performed by incubation with Triton X-100 to a final concentration of 1% for 1 hour 11 and stored at -189 80°C until testing for the presence of SARS-CoV-2 specific antibodies. Serum samples were collected 190

from December 2020 to February 2021 between the two peaks of SARS-CoV-2 transmissions in Ethiopia 191

(https://covid19.who.int/region/afro/country/et).

Enzyme-Linked Immunosorbent Assay (ELISA) 193

The SARS-CoV-2 spike protein Receptor Binding Domain (RBD)-containing plasmid construct was 194 cloned as described previously 12 . The RBD protein was then expressed in EXPi293 cells using previous 195 methods 12 . Then, the purified RBD protein was used as a target antigen to develop our in-house anti-196 SARS-CoV-2 RBD IgG detection ELISA. We used 1µg/ml of RBD to coat the microwell plate overnight 197

at 4 0 C. The assay is an indirect ELISA, measuring serum IgG against RBD of spike protein SARS-CoV-198 2, using a horseradish peroxidase-linked anti-human IgG secondary antibody (Invitrogen, USA). 199

Supplementary method shows the detail procedure description of our assay (Supplementary Method). We titer antibody), 20/124 (low S1, high-nucleocapsid protein antibody titer), 20/126 (low-titer antibody, 209 20/128, negative control).

We noted background signal from the negative controls at a 1:100 dilution of serum. Of 365 pre-COVID-212

19 sera, 30 showed optical density (OD) values comparable to the low reactive convalescent WHO 213 plasma samples. We further optimized the assay by increasing the concentration of skimmed milk powder 214

and Tween-20 in blocking buffer from 3% to 4% and from 0.05% to 0.1%, respectively, and serum 215 dilution at 1:200. Except for fourteen pre-COVID-19 samples, the background was significantly reduced 216 when re-tested false positives, which in turn increased the specificity of our assay without compromising 217

its sensitivity in WHO positive control samples and serum samples obtained from a cohort of COVID-19 218

patients. 219

Using our optimized ELISA protocol, we calculated the cut-off value for positivity using pre-COVID-19 220 pandemic sera collected between 2012 and 2018, and plasma/serum samples collected from cohort of 221 confirmed COVID-19 patients at different time points of post-onset of symptoms (dps). The definition of 222 seropositivity represents a greater than 2.5 ratio of sample OD value to the mean OD value of the negative 223 controls (Fig 1) . This definition provides specificity of 97.7% (95% CI, 95.6-99.0) ( respectively from mostly (>90%) mild and moderate COVID-19 cases confirmed by RT-PCR (Table S2) . 227

This performance is in line with those published for both in-house and commercial assays approved for 228 emergency use by the FDA 13 . 229

and https://covid-19-diagnostics.jrc.ec.europa.eu/.]. 230

In-house IgG ELISA comparison with commercial anti-SARS-CoV-2 serologic assays 231

We further compared the relative sensitivity and specificity of our assay with commercially available 232 SARS-CoV-2 antibody tests: one lateral flow assay (LFA) (Hangzhou Realy Tech Co., LTD) and one 233 ELISA (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd) following the manufacturers" 234 instructions using randomly selected small panels (pre-pandemic; n=40, and COVID-19; n=40) from the 235 large size panels that were used for our assay validation. We found a comparable sensitivity and 236 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.01.21259687 doi: medRxiv preprint specificity to those commercially available COVID-19 antibody detection kits depending on the sample 237 collection date (Table S3 and Table S4 ). We then utilized this assay to estimate the seroprevalence of 238

anti-SARS-CoV-2 spike protein RBD IgG antibodies among HWS. 239 240 241

Data analysis 242

The is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. Interpretation of SARS-CoV-2 serologic test results, except pan Igs Wanti ELISA, has been reported to 295 be very challenging in Africa due to pre-existing cross-reactive antibodies induced by other pathogens 296

such as non-SARS-CoV-2 human coronaviruses and malaria parasites 14 . Given the rapid decline of anti-297 SARS-CoV-2 nucleocapsid antibodies as compared to the anti-RBD IgG antibody 13 , we developed and 298

optimized an in-house ELISA that detects anti-SARS-CoV-2 IgG antibodies. Our assay, unlike other 299 commercially available serologic assays, is affordable and has been validated with a large number of 300

Ethiopian sera from both pre-COVID-19 and COVID-19 patients from the same regions. Its sensitivity on 301 convalescent sera from COVID-19 patients confirmed by RT-PCR was found to be as sensitive as the 302

Wantai pan Ig ELISA (100%), and superior to Realy Tech"s IgM/IgG LFA (90%). Also, our in-house 303 assay displayed 97.7% specificity in randomly selected pre-COVID-19 Ethiopian origin sera, which is 304 superior to Realy Tech (92.5 %).

Seroprevalence studies provide information about the extent of individuals who had exposure to to the 306 virus and help to understand the future course of the pandemic and are key to providing target prevention 307

and control measures in reducing transmission and severe outcomes 15 . In this study, the overall 308 seroprevalence of SARS-CoV-2 spike RBD IgG antibodies among HWs was 39.6%, ranging from 24.5% 309

in the Hiwot Fana Specialized Hospital, Harar to 48·0% in ALERT Hospital located in the capital city, 310

Addis Ababa. This is not a surprise given Addis Ababa is the epicenter of SARS-CoV-2 transmission in 311

Ethiopia, and SARS-CoV-2 has been introduced 4 months later in Harar. As a result of which, it is 312 expected that a higher proportion of HWs in hospitals located in Addis Ababa, including ALERT are 313 frequently exposed to COVID-19 cases than that HWs working in hospitals located in Harar, where fewer 314 number cases and deaths had been reported.

According to our finding, at least 4 in 10 urban Ethiopian HWs had already been exposed to SARS-CoV-316 2 by February 2021 in Ethiopia. This result contrasts with a serosurvey in asymptomatic individuals from 317 the general population conducted in March 2020 in Addis Ababa (8.8%) 16 and from the household 318 serosurveys in Jimma (2%) and Addis Ababa (5%) that were conducted during the first wave of the 319 pandemic-i.e., four months after the first COVID-19 case in Ethiopia 17 . Although this stark 320 seroprevalence difference between our study and these two previous studies might be explained by 321 differences in the types of assays employed, lack of personal protective equipment (PPE) and/or 322 respective cohorts, the most plausible explanation is that the sera for the present serosurveillance study 323 had been collected after the first wave of the pandemic in Ethiopia, between March 2020 and February 324 2021.

While the high seroprevalence rates observed among the different geographically located hospitals are 326 approaching those of high-incidence countries like Brazil 18 , they are in agreement with several other 327 SARS-CoV-2 seroprevalence studies from sub-Saharan Africa that, like Ethiopia, have reported much 328 lower rates of RT-PCR confirmed cases and deaths. For example, higher anti-SARS-CoV-2 antibody 329 seroprevalence has been reported in South Sudan (30% to 60.6%) 19 , Democratic Republic of Congo (8%-330 36) 20 and Nigeria (25%-45) 21 depending on the population sampled and the serological test use. Taken  331 together these studies indicate that SARS-CoV-2 has spread widely in sub-Saharan Africa 22 . However, 332

the majority (74.0%) of our study participants never had any symptoms compatible with COVID-19, 333

suggesting the occurrence of significant burden of asymptomatic infections and its transmissions in the 334 country, which is now, being reflected in the trend of increasing PCR positivity since January 2021. The 335

higher proportion of younger HWs (mean age of 34 years), and the fewer participants with comorbidities 336 (6.7%) may have contributed to the observed high burden of asymptomatic infection among the studied 337 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. African countries such as in Malawi 24 . These findings and ours highlight the importance of asymptomatic 343

infections in the African countries. Interestingly, we found no seroprevalence differences between 344 healthcare occupations including administrative staff. The lack of a dramatic difference between front line 345

HWs and administrators may be a reflection of the frontline administrative staff are also at high risk and 346 are poorly protected , or may suggest the level of virus transmission in the general population at large as 347

previously observed in UK 9 . Nevertheless, further well-designed investigations are required to implement 348 occupation-specific public health strategies in healthcare facilities. 349

In the present study, a history of previous close contact with a suspected or confirmed COVID-19 case 350 was found to be strongly associated with seropositivity; however, this finding contradicts the observed 351 similar seropositivity between front line HWs and administrators. Similar odds of seropositivity between 352 males and females were also found although several studies elsewhere reported higher odds of 353 seropositivity in males 25 . A similar contradictory finding was reported in the Spanish general 354 population 23 .

Our study has several strengths. These include its use of an in-house developed assay which we optimized 356

to significantly minimize false positive responses by validating it with both pre-pandemic and pandemic 357 samples of Ethiopian origin. Most importantly, the study involved a relatively large sample size from five 358 hospitals located in different geographical locations, providing much needed information about the 359 COVID-19 pandemic in sub-Saharan Africa. 360

Despite these strengths, our study has several limitations. First, all hospital staff were invited to take part 361 in the study, and hence selection bias might have affected our results. Second, recall bias might have 362

affected the responses to the history of symptoms compatible with COVID-19, and close contact with a 363

confirmed COVID-19 case, and thereby contributed to the absence of a strong correlation between 364 seropositivity and these covariates, albeit having close contact with COVID-19 case. Third, our findings 365 are slightly affected by the accuracy of our assay, with a sensitivity of 100% in convalescent samples 366 from RT-PCR conformed COVID-19 cases and specificity of 97.7% in pre-COVID-19 samples. 367

However, even this slight overestimation of the apparent seroprevalence associated with the assay 368 specificity is likely to be matched by the proportion of study participants who might be infected and yet 369 not produce humoral immune responses at the time of blood sample collection. 370

In conclusion, we developed an in-house IgG ELISA that meets the WHO requirements to be utilized for 371 SARS-CoV-2 serosurveillance studies. This seroprevalence study revealed a remarkably high 372 seroprevalence (40-48%) of SARS-CoV-2 among HWs in the five public hospitals; with slight 373 differences amongst hospitals, except Hiwot Fana Specialized Hospital in which relatively lowest (24.5%) 374 seroprevalence was found. We found no seroprevalence rate differences between front line HWs and 375

administrative staff, indicating the observed high seroprevalence of SARS-CoV-2 might also be a 376 reflection of the community transmission. Taken together these findings suggest extensive cryptic 377 circulation (asymptomatic transmission) of SARS-CoV-2 in Ethiopia. Whether the detected anti-SARS-378

CoV-2 antibodies can persist adequately and confer protection from subsequent infections to those HWs 379 who had or had not received COVID-19 vaccine will require further immunological investigation. 380

Acknowledgements 381

We thank study participants and AHRI"s SARS-CoV-2 diagnostic and research team members. We also 382 thank Mr. Mekonnen Ashagarie, Director of American Health and Home Care, MA, USA for the non-383 technical support. 384

TG, AM, AMi MA, AA and FG conceived the study. TG, BS, AM, and AA wrote the first draft of the 386 protocol, and revised by all authors. TG, AM, MA, AA and FGT developed the serologic assay, TAB 387 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.01.21259687 doi: medRxiv preprint purified the antigen. TG, BS, AM, AMi and AA coordinated the sample collection. BG, AS, YM, YM, 388

ZT, DK, AG, DA and ET collected the blood samples and data. BT, MO, GJ, AA, AH and DT conducted 389 the sample testing, TH cleaned the data, TH and TG analysed the data, TG accessed and verified the data 390

underlying the study and take responsiblity for the data. TG and AA drafted the manuscript. All authors 391 edited the final manuscript. All authors contributed to study design, revising the protocol and the 392 manuscript for important intellectual content. TG, AA, FGT were responsible for the decision to submit 393

for publication, and approved the final submitted version of the manuscript. 394 457 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. (Table S2) . We also tested serum/plasma samples collected from 365 465 Ethiopian individuals before the global COVID-19 pandemic, represented in blue color (Table S1 ). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.01.21259687 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.01.21259687 doi: medRxiv preprint 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.01.21259687 doi: medRxiv preprint

COVID-19) -Africa CDC

Socio-demographic and epidemiological consideration of Africa"s 398 COVID-19 response: what is the possible pandemic course

High prevalence of pre-existing serological cross-reactivity 400 against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

The effect of Bacillus Calmette-Guérin 403 (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for 404 the COVID-19 pandemic

Less Severe Cases of COVID-19 in 406

Africa: Could Co-infection or a Recent History of Plasmodium falciparum Infection Be 407 Protective?

Estimates of the severity of coronavirus disease 2019: a model-409 based analysis

Seroprevalence of antibodies against SARS-414

CoV-2 among health care workers in a large Spanish reference hospital

COVID-19: PCR screening of asymptomatic health-care 416 workers at London hospital

Solidarity 2" global serologic study for COVID-19

Persistence of serum and saliva antibody responses to SARS-CoV-2 421 spike antigens in COVID-19 patients

Cross-reactivity of SARS-CoV 423 structural protein antibodies against SARS-CoV-2

Limited specificity of commercially available SARS-CoV-426

IgG ELISAs in serum samples of African origin

Seroepidemiologic Study Designs for Determining SARS-COV-429 2 Transmission and Immunity

Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis 431

Prevalence of SARS-CoV-2 in urban and rural Ethiopia: 433 Randomized household serosurveys reveal level of spread during the first wave of the pandemic

COVID-19 herd immunity in the Brazilian Amazon

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba

South Sudan: a population-based study

High SARS-CoV-2 Seroprevalence in Healthcare 441 Workers in Bukavu, Eastern Democratic Republic of Congo

SARS-CoV-2 Seropositivity in Asymptomatic Frontline Health Workers in Ibadan

Seroprevalence surveys in sub-Saharan Africa: what do they tell us? Lancet Glob 446

ENE-COVID): a nationwide, population-based 448 seroepidemiological study -The Lancet

CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in 451 urban Malawi | medRxiv

Seroprevalence of SARS-CoV-2 antibodies and 454 associated factors in healthcare workers: a systematic review and meta-analysis